Special Delivery
Executive Summary
Thanks to injection-only delivery, large-molecule drugs have always been seen by Big Pharma as marketplace duds. Companies with delivery alternatives have languished in the dark. Someone's turned the light on.
You may also be interested in...
A Coup for Nobex
Large pharma companies haven't set a high priority on developing new drug delivery formulations for their existing portfolios; nor have they been interested in macromolecule development. Thus, the strategic alliance forged in May between giant GSK and small drug-delivery firm Nobex is noteworthy. Not only is it one of the largest deals of its kind, but it also focuses on development of oral insulin for diabetic patients, which presents a challenge that few have attempted to overcome.
Can Organovo Leverage Its Solid Phase II Data In MASH?
Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.